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a  b  s  t  r  a  c  t
INTRODUCTION:  Malignant  pheochromocytoma  represents  10%  of  all patients  with pheochromocytoma.
Of  these  cases,  only  5–9%  presents  without  elevation  of  metanephrines  and  catecholamines.
PRESENTATION  OF  CASE:  A  43-year-old  female  patient  presented  with  an  abdominal  tumor.  An exploratory
laparotomy  was  performed  and  the ﬁnal  report  was  a pheochromocytoma.  After ten  years,  multiple
liver  lesions  were  detected  and  surgical  treatment  was  performed.  Pathological  evaluation  revealed  a
malignant  pheochromocytoma  with  negative  margins  after  5 years  of follow-up  without  evidence  of
disease.
DISCUSSION:  The  recurrence  rate of  malignant  pheochromocytoma  is  15–20%  at  ten  years  and  a  5-year
survival  rate  that  ranges  from  50%  to 80%.  The  presence  of  synchronous  metastases  is rare  (10–27%),  buttanephrines - Catecholamines have  been  reported  until  20 years  later  with  the  most  common  metastatic  sites  being the local  lymph
nodes,  bone  (50%),  liver  (50%)  and lung  (30%).  The  prognostic  factor  such  as  size  >6 cm,  age  over  45  years,
synchronous  metastasis  and no  tumor  excision  are  related  with  poor  prognosis.
CONCLUSION:  Surgical  treatment  offers the  best  survival  rate and the  only  chance  of  cure  so  far  and  the
goal  is  an R0  resection  as  in  our case.  So it should  be  the treatment  of  choice.
© 2016  The  Authors.  Published  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Pheochromocytomas are neuroendocrine tumors from chro-
afﬁn cells of the adrenal medulla, with a prevalence in the general
opulation of only 2 cases per million. It is estimated that up to 5%
f patients presenting with adrenal incidentalomas are found to
ave pheochromocytomas. [1,13]. Of this, only 10% are malignant
heochromocytoma characterized by the presence of metastasis
hich spread to organs where no chromafﬁn cells are present. [1].
The clinical presentations in approximately 40–88% are the
lassic symptoms of headaches, sweating, palpitations, and parox-
smal or sustained hypertension, but might be asymptomatic as
ell [2,12]. Hypertension represents the main morbidity and mor-
ality risk factor. It requires specialized handling especially in
atients who are candidates for surgery. The diagnosis requires
 Key learning points: (1) Metastatic pheochromocytoma (2) Metastatic pheochro-
ocytoma to liver.
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biochemical test but they not always rise (4–9%) and there is no
way to differentiate the malignant variant [1,2,13].
The location of the tumor is essential in patients with resectable
metastasis because surgery offers the only chance of cure and the
best survival rate of 80% at 5 years [1,2,5]. MRI  has a higher sensi-
tivity and speciﬁcity in the case of hepatic metastasis. [2,9]. Today
the PET/CT with FDG is the study of choice compared with CT and
other functional studies 123I-MIBG [2,10].
Symptomatic treatment with alpha- and beta-adrenergic
blockade should be offered to patients with good results.
Systemic chemotherapy, radiopharmaceutical therapy using beta-
emitting isotopes coupled with metaiodobenzylguanidine (MIBG)
or somatostatin analogue had poor results. [1,2]. The molecular tar-
geting therapies such as Sunitinib seem to have adverse effects
particularly some mutations (SDH/VHL) [7]. Surgical resection is
the only curative therapeutic modality. However, rarely feasible,
the resection of hepatic metastases improve symptoms and sur-
vival [1,2,5].roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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uFig. 2. Abdominal ultrasound
. Clinical case
A 43-year-old female patient with antecedent ovarian cystade-
oma was admitted in our institute with 1-year history of lower
bdominal pain. Patient evaluation revealed a non-painful, ﬁrm
bdominal mass, of 5 × 6 cm diameter in the right ﬂank. Complete
nalysis and tumors markers were negative for germ cell tumor
alpha-fetoprotein and human chorionic gonadotropin). Abdomi-
al computerized tomography scan (CT) showed a solid mass, with
entral necrosis, located in the hepatorenal space as incidentaloma
ith negative metanephrines and catecholamines.
We decided a surgical treatment. An exploratory laparotomy
as performed and right nephrectomy, ﬁnding a tumor above the
pper pole of the right kidney with inﬁltration of the inferior vena
ava. No intraoperative complications were reported and the post-
perative course was successful. Pathologic evaluation revealed
 pheochromocytoma conﬁrmed by immunohistochemistry (pos-
tive in chromogranin A, S100 protein, inaptoﬁsin and imentin,
egative in CK −7). (Fig. 11.1, 1.2)
The patient was under surveillance without recurrence for 10
ears, abdominal ultrasound showed a 4 × 5 cm mass in segments
VA and V of the liver. (Fig. 2). The magnetic resonance revealed
esions in liver suggestive of malignancy in segments IVA, VI and
II (Fig. 3). CT − guided biopsy was performed and reported
etastatic pheochromocytoma, with negative metanephrines and
atecholamines test. During follow-up chromogranin A was not
sed because there is no evidence to support this.ing a 4 × 5 cm mass in liver.
VI and VII segmentectomies of the liver were performed, suspi-
cious lesions were found in II and IVA segments, so we decided to
make metastasectomy of these lesions, with four metastatic lesions
resected in total. The pathological evaluation revealed a malignant
pheochromocytoma in all segments of liver with negative margins
(Fig. 4 4.1, 4.2, 4.3).
There is no evidence of recurrence after 5 years of surveil-
lance after last surgery. At the time, the patient is completely
asymptomatic, with negatives CT scans and normal measure-
ments of urinary and plasma fractionated metanephrines and
catecholamines during follow- up.
3. Discussion
Pheochromocytomas are neuroendocrine tumors from chro-
mafﬁn cells of the adrenal medulla having a prevalence in the
general population of only 2 cases per million, it is estimated
that up to 5% of patients presenting with adrenal incidentalomas
are found to have pheochromocytomas. [1,13]. The characteris-
tic of malignant pheochromocytoma is the presence of metastasis
which spread to organs where no chromafﬁn cells are present.
Approximately 10% of pheochromocytomas are malignant [1]. The
recurrence rate is 15–20% at ten years and a 5-year survival rate
that ranges from 50% to 80% [1,2]. The presence of synchronous
metastases is rare (10–27%), but have been reported until 20 years
later with the most common metastatic sites being the local lymph
nodes, bone (50%), liver (50%) and lung (30%) [1,3]. The prognostic
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fFig. 4. 4.1.) Hepatic segmentectomy. 4.2.) Hepatic segmentectomy. 2 nodu
actor such as size >6 cm,  age over 45 years, synchronous metastasis
nd no tumor excision are related with poor prognosis [1].
Genetic alterations of these genes are associated with tran-
criptome changes and are divided into 2 main clusters: cluster
 including the von Hippel-Lindau (VHL) gene, the succinate
ehydrogenase (SDH) complex, the fumarate hydratase (FH), the
ypoxia-inducible factor 2-alpha (HIF2A) and the propyl hydrox-
lase domain-containing protein 1 and 2 (PHD1, PHD2) genes;
nd cluster 2 including the rearranged during transfection proto-
ncogene (RET), the neuroﬁbromin 1 (NF1), the transmembrane
rotein 127 (TMEM 127) and the Myc-associated factor X (MAX)
enes [4]. A germline mutation in one of the susceptibility genes
dentiﬁed so far explains approximately 40% of cases with the
emaining 60% considered to be sporadic. [2]. The only predictor
f malignancy is the SDHB gene germline mutation as it is found in
ore than 40% of cases and are associated with response to temo-
olomide [12]. The clinical presentation is similar to non-malignant
orm, 40 to 88% presents with headaches, sweating, palpita-orly deﬁned, ﬂe. 4.3.) Pathologycal evaluation. Liver parenchyma inﬁltrate.
tions, and paroxysmal or sustained hypertension, non-secreting
benign pheochromocytomas are presented as incidentalomas, a
recent study show that they are more likely to present with ver-
tigo/dizziness than those with positive tumor markers (28% vs 3%)
[2,13]. There are no data in the medical literature of the clini-
cal presentation in patients with malignant pheochromocytomas
without elevation of metanephrines and catecholamines. The ini-
tial biochemical test is the measurement of free plasma and urinary
fractionated metanephrines, a more than fourfold elevation is asso-
ciated with a 100% probability [8]. But they not always rise (4–9%)
and there is no way to differentiate the malignant variant as in this
case report [1,2,13].
Both MRI  and CT exert a 85–100% sensitivity with a 50% speci-
ﬁcity, and are important in the planning of surgical treatment. The
size of tumor >45 mm is one of the important features that suggest
malignancy. MRI  has a higher sensitivity and speciﬁcity for staging
and follow-up especially in the case of hepatic metastasis. [2,9] Cur-
rently, the PET/CT with FDG is the study of choice for the anatomic
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ocation compared with CT and other functional studies 123I-MIBG
2,10].
The Adrenal gland Scaled Score (PASS) is the main histologi-
al tool to separate benign from malignant pheochromocytoma, a
ut of >4 has a sensitivity of 50% and speciﬁcity of 45% to separate
umors with a potential for a biologically aggressive behavior [11].
urrently, no absolute molecular or immunohistochemical marker
s available to differentiate malignant pheochromocytoma, but a
ut of >3 Ki-67/Mib-1 nuclear antigen is correlating mostly with
ggressive behavior [1].
Symptomatic treatment with alpha- and beta-adrenergic block-
de in lytic bone metastases with the use of bisphosphonates,
adiotherapy or radiofrequency ablation with good results is advis-
ble. The strategy of wait and see its a good option for asymptomatic
atients, 50% of patients had stable disease after 1 year of follow-up,
equires monitoring with paraclinical studies and progression (20%
y RECIST criteria) is indicative of disease intervention [2]. Systemic
hemotherapy responses of 65% the combination with cyclophos-
hamide, vincristine and dacarbazine. Other alternative regimens
nclude etoposide and cisplatin, anthracycline plus CVD and arabi-
oside. Its preferred in rapidly progressive tumors [2]. CVD obtains
7% tumor and 40% hormonal response, complete remission in only
% of patients. The overall median survival varies from 24 months
o 6 years depending on catecholamine and tumor response and the
edian progression-free survival ranges from 20 to 40 months [6].
adiopharmaceutical therapy using beta-emitting isotopes cou-
led with metaiodobenzylguanidine (MIBG) with responses partial
esponse (RECIST criteria) of 84.6% or somatostatin analogue with
oor results. [1,2]. The molecular targeting therapies under study
ave shown a role of inhibiting tyrosine kinase such as Sunitinib
ith beneﬁt in metastatic SDH or VHL mutated [7]. All these thera-
ies have been unsatisfactory. Surgical resection is the only curative
herapeutic modality. However, rarely feasible, the resection of
epatic metastases improve symptoms and survival, the effect is
reater in patients with a Ki–67 <20% and R0 resection [1,2,5].
We present a patient who presents with incidentaloma which
aused an exploratory laparotomy reaching the diagnosis of
heochromocytoma. During follow-up ten years after, multiple
iver lesions were detected with negative metanephrines and cat-
cholamines test, CT-guided biopsy was performed and reported
etastatic pheochromocytoma. We  decided to perform a segmen-
ectomy of VI and VII and metastasectomy of the segments II and
Va with R0 margins. A 5-year follow-up was without evidence of
isease.
. Conclusions
The malignant pheochromocytoma is a rare entity. We  present a
ase without elevation of biochemical markers and asymptomatic
hich is extremely rare. Based on this case, we recommend fol-
owing up with US, CT or MRI  in patients with pheochromocytoma
reated indeﬁnitely because metachronous metastasis may  appear.
inding liver lesions should make us think about the malignant vari-
nt. Surgical treatment offers the best survival rate and the only
hance of cure so far and the goal is an R0 resection as in our case.
o it should be the treatment of choice
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